Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12‐month outcomes of BIOSOLVE‐II and BIOSOLVE‐III

OBJECTIVES: Based on outcomes of the BIOSOLVE‐II study, a novel second generation drug‐eluting absorbable metal scaffold gained CE‐mark in 2016. The BIOSOLVE‐III study aimed to confirm these outcomes and to obtain additional 12‐month angiographic data. BACKGROUND: Bioresorbable scaffolds are intende...

Descripción completa

Detalles Bibliográficos
Autores principales: Haude, Michael, Ince, Hüseyin, Kische, Stephan, Abizaid, Alexandre, Tölg, Ralph, Alves Lemos, Pedro, Van Mieghem, Nicolas M., Verheye, Stefan, von Birgelen, Clemens, Christiansen, Evald Høj, Barbato, Emanuele, Garcia‐Garcia, Hector M., Waksman, Ron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Coronary Artery Disease (E‐only Articles)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586164/
https://www.ncbi.nlm.nih.gov/pubmed/30079472
http://dx.doi.org/10.1002/ccd.27680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586164/
https://www.ncbi.nlm.nih.gov/pubmed/30079472
http://dx.doi.org/10.1002/ccd.27680

Ejemplares similares